268 related articles for article (PubMed ID: 25039741)
21. Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).
Nguyen A; Xie P; Litvinov IV; Lefrançois P
Am J Clin Dermatol; 2023 May; 24(3):359-374. PubMed ID: 36795228
[TBL] [Abstract][Full Text] [Related]
22. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
23. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
Tauber G; Pavlovsky L; Fenig E; Hodak E
J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
[TBL] [Abstract][Full Text] [Related]
28. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
29. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
30. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
31. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
32. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
[TBL] [Abstract][Full Text] [Related]
33. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects.
Bánvölgyi A; Anker P; Lőrincz K; Kiss N; Márton D; Fésűs L; Gyöngyösi N; Wikonkál N
J Dermatolog Treat; 2020 Jun; 31(4):387-398. PubMed ID: 31039644
[No Abstract] [Full Text] [Related]
34. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
35. Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.
Edwards BJ; Raisch DW; Saraykar SS; Sun M; Hammel JA; Tran HT; Wehr N; Arabyat R; West DP
Drugs R D; 2017 Mar; 17(1):211-218. PubMed ID: 28063021
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
39. Skin eruption and cholestatic hepatic injury due to vismodegib.
Drago F; Trave I; Wei Y; Parodi A
G Ital Dermatol Venereol; 2019 Aug; 154(4):496-497. PubMed ID: 29199802
[No Abstract] [Full Text] [Related]
40. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
